SLC5A2 and metabolic dysfunction-associated steatotic liver disease: EMPA is an oral hypoglycemic drug, which represents SGLT2 inhibitor candidates in renal tissues (J Levine 2017), improves hepatic insulin sensitivity, and additionally, it decreases hepatic lipid accumulation indeed in NAFLD progression (Chehrehgosha et al. 2021, Androutsakos et al. 2022).